On Monday, MaxCyte Inc (NASDAQ: MXCT) opened higher 15.83% from the last session, before settling in for the closing price of $3.60. Price fluctuations for MXCT have ranged from $3.16 to $5.55 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 20.83%. Company’s average yearly earnings per share was noted -11.97% at the time writing. With a float of $97.34 million, this company’s outstanding shares have now reached $105.30 million.
Let’s determine the extent of company efficiency that accounts for 143 employees. In terms of profitability, gross margin is 79.04%, operating margin of -101.56%, and the pretax margin is -78.36%.
MaxCyte Inc (MXCT) Insider Activity
A key investor’s attitude towards the stock of the Medical Devices industry is another important factor to consider. The insider ownership of MaxCyte Inc is 7.72%, while institutional ownership is 65.12%. The most recent insider transaction that took place on Nov 01 ’24, was worth 177,403. In this transaction Director of this company sold 47,689 shares at a rate of $3.72, taking the stock ownership to the 269,118 shares. Before that another transaction happened on Oct 28 ’24, when Company’s Director sold 3,000 for $3.72, making the entire transaction worth $11,166. This insider now owns 141,950 shares in total.
MaxCyte Inc (MXCT) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around -11.97% per share during the next fiscal year.
MaxCyte Inc (NASDAQ: MXCT) Trading Performance Indicators
Check out the current performance indicators for MaxCyte Inc (MXCT). In the past quarter, the stock posted a quick ratio of 9.22. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 9.65.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.34, a number that is poised to hit -0.12 in the next quarter and is forecasted to reach -0.38 in one year’s time.
Technical Analysis of MaxCyte Inc (MXCT)
Looking closely at MaxCyte Inc (NASDAQ: MXCT), its last 5-days average volume was 0.57 million, which is a jump from its year-to-date volume of 0.54 million. As of the previous 9 days, the stock’s Stochastic %D was 68.72%. Additionally, its Average True Range was 0.23.
During the past 100 days, MaxCyte Inc’s (MXCT) raw stochastic average was set at 52.89%, which indicates a significant decrease from 84.81% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 71.71% in the past 14 days, which was higher than the 57.02% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.65, while its 200-day Moving Average is $4.12. However, in the short run, MaxCyte Inc’s stock first resistance to watch stands at $4.46. Second resistance stands at $4.76. The third major resistance level sits at $5.16. If the price goes on to break the first support level at $3.76, it is likely to go to the next support level at $3.36. Should the price break the second support level, the third support level stands at $3.06.
MaxCyte Inc (NASDAQ: MXCT) Key Stats
There are currently 105,691K shares outstanding in the company with a market cap of 439.86 million. Presently, the company’s annual sales total 41,290 K according to its annual income of -37,920 K. Last quarter, the company’s sales amounted to 8,160 K and its income totaled -11,560 K.
